134 related articles for article (PubMed ID: 6204368)
21. Differences in conformation of type 3 poliovirus antigenic sites on non-infectious empty particles and infectious virus.
Ferguson M; Minor PD
J Gen Virol; 1990 Jun; 71 ( Pt 6)():1271-4. PubMed ID: 1693661
[TBL] [Abstract][Full Text] [Related]
22. Different virus-precipitating activities of neutralizing monoclonal antibodies that recognize distinct sites of poliovirus particles.
Taniguchi K; Urasawa S
Arch Virol; 1987; 92(1-2):27-40. PubMed ID: 2432854
[TBL] [Abstract][Full Text] [Related]
23. Ability of linear and cyclic peptides of neutralization antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralizing antibodies.
van der Werf S; Briand JP; Plaué S; Burckard J; Girard M; Van Regenmortel MH
Res Virol; 1994; 145(6):349-59. PubMed ID: 7535942
[TBL] [Abstract][Full Text] [Related]
24. Reactivity of anti-peptide and anti-poliovirus type 3 monoclonal antibodies with synthetic peptides.
Ferguson M; Reed SE; Minor PD
J Gen Virol; 1986 Nov; 67 ( Pt 11)():2527-31. PubMed ID: 2431104
[TBL] [Abstract][Full Text] [Related]
25. Preliminary studies on antigenic variation of poliovirus using neutralizing monoclonal antibodies.
Guo R; Tang EH; Wang H; Yang XF; Liu MY; Qin HX; Li QH; Zhuang JY; Liu KM
J Gen Virol; 1987 Apr; 68 ( Pt 4)():989-94. PubMed ID: 3033136
[TBL] [Abstract][Full Text] [Related]
26. Antigenicity and immunogenicity of poliovirus capsid proteins.
van Wezel AL; van der Marel P; Hazendonk TG; Boer-Bak V; Henneke MA
Dev Biol Stand; 1983; 55():209-15. PubMed ID: 6203795
[TBL] [Abstract][Full Text] [Related]
27. Neutralization epitope patterns of poliovirus strains isolated from paralytic cases.
Crainic R; Blondel B; Aubert-Combiescu A; Beytout D; Couillin P; Candrea A; Boué A; Horaud F
Dev Biol Stand; 1984; 57():165-70. PubMed ID: 6084607
[TBL] [Abstract][Full Text] [Related]
28. Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization.
Emini EA; Ostapchuk P; Wimmer E
J Virol; 1983 Nov; 48(2):547-50. PubMed ID: 6194315
[TBL] [Abstract][Full Text] [Related]
29. A hybridoma cell line secreting antibody to poliovirus type 3 D-antigen: detection in virus harvest of two D-antigen populations.
Ferguson M; Schild GC; Minor PD; Yates PJ; Spitz M
J Gen Virol; 1981 Jun; 54(Pt 2):437-42. PubMed ID: 6270261
[TBL] [Abstract][Full Text] [Related]
30. Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3.
Evans DM; Minor PD; Schild GS; Almond JW
Nature; 1983 Aug 4-10; 304(5925):459-62. PubMed ID: 6192344
[TBL] [Abstract][Full Text] [Related]
31. WHO collaborative study on the use of monoclonal antibodies for the intratypic differentiation of poliovirus strains.
Ferguson M; Magrath DI; Minor PD; Schild GC
Bull World Health Organ; 1986; 64(2):239-46. PubMed ID: 3017595
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the antibodies elicited by the individual structural polypeptides of foot-and mouth disease and polio viruses.
Meloen RH; Rowlands DJ; Brown F
J Gen Virol; 1979 Dec; 45(3):761-3. PubMed ID: 94352
[TBL] [Abstract][Full Text] [Related]
33. Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B.
Orvell C; Norrby E; Mufson MA
J Gen Virol; 1987 Dec; 68 ( Pt 12)():3125-35. PubMed ID: 2447224
[TBL] [Abstract][Full Text] [Related]
34. Studies of the antigenic variation in poliovirus type 1. Selection and analysis of variant strains with monoclonal antibodies by neutralization.
Thibodeau L; Lacroix M; Lecomte J; Fauvel M
Dev Biol Stand; 1984; 57():157-63. PubMed ID: 6084606
[TBL] [Abstract][Full Text] [Related]
35. Production and characterization of neutralizing monoclonal antibodies against poliovirus type 1, 2, and 3.
Payment P; Trudel M; Thibodeau L; Lecomte J
Can J Microbiol; 1989 May; 35(5):550-3. PubMed ID: 2545322
[TBL] [Abstract][Full Text] [Related]
36. Monoclonal antibodies reactive with different sites of N and H antigenic particles of poliovirus.
Taniguchi K; Urasawa S; Urasawa T
J Gen Virol; 1983 Dec; 64 ( Pt 12)():2803-8. PubMed ID: 6198442
[TBL] [Abstract][Full Text] [Related]
37. Binding site of neutralizing monoclonal antibodies obtained after in vivo priming with purified VP1 of poliovirus type 1 is located between amino acid residues 93 and 104 of VP1.
Wiegers KJ; Dernick R
Virology; 1987 Mar; 157(1):248-51. PubMed ID: 2435056
[TBL] [Abstract][Full Text] [Related]
38. Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak.
Shaw J; Jorba J; Zhao K; Iber J; Chen Q; Adu F; Adeniji A; Bukbuk D; Baba M; Henderson E; Dybdahl-Sissoko N; McDonald S; Weldon WC; Gumede N; Oberste MS; Kew OM; Burns CC
J Virol; 2018 May; 92(9):. PubMed ID: 29444940
[TBL] [Abstract][Full Text] [Related]
39. The reactions of monoclonal antibodies with structural proteins of mumps virus.
Orvell C
J Immunol; 1984 May; 132(5):2622-9. PubMed ID: 6201553
[TBL] [Abstract][Full Text] [Related]
40. Isolated poliovirus capsid protein VP1 induces a neutralizing response in rats.
Chow M; Baltimore D
Proc Natl Acad Sci U S A; 1982 Dec; 79(23):7518-21. PubMed ID: 6296837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
